Logo image of KDNY

CHINOOK THERAPEUTICS INC (KDNY) Stock Fundamental Analysis

NASDAQ:KDNY - Nasdaq - US16961L1061 - Common Stock - Currency: USD

40.39  +0.09 (+0.22%)

After market: 40.32 -0.07 (-0.17%)

Fundamental Rating

3

KDNY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While KDNY has a great health rating, there are worries on its profitability. KDNY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KDNY has reported negative net income.
In the past year KDNY has reported a negative cash flow from operations.
In the past 5 years KDNY always reported negative net income.
KDNY had a negative operating cash flow in each of the past 5 years.
KDNY Yearly Net Income VS EBIT VS OCF VS FCFKDNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M

1.2 Ratios

The profitability ratios for KDNY are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KDNY Yearly ROA, ROE, ROICKDNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KDNY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KDNY Yearly Profit, Operating, Gross MarginsKDNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

KDNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KDNY has been increased compared to 1 year ago.
There is no outstanding debt for KDNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KDNY Yearly Shares OutstandingKDNY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
KDNY Yearly Total Debt VS Total AssetsKDNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 10.57 indicates that KDNY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.57, KDNY belongs to the top of the industry, outperforming 88.27% of the companies in the same industry.
There is no outstanding debt for KDNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.57
ROIC/WACCN/A
WACC9.21%
KDNY Yearly LT Debt VS Equity VS FCFKDNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M 400M

2.3 Liquidity

KDNY has a Current Ratio of 5.82. This indicates that KDNY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of KDNY (5.82) is comparable to the rest of the industry.
A Quick Ratio of 5.82 indicates that KDNY has no problem at all paying its short term obligations.
KDNY has a Quick ratio (5.82) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.82
Quick Ratio 5.82
KDNY Yearly Current Assets VS Current LiabilitesKDNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

KDNY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.06%.
The Revenue for KDNY has decreased by -89.24% in the past year. This is quite bad
KDNY shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.69% yearly.
EPS 1Y (TTM)-107.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.1%
Revenue 1Y (TTM)-89.24%
Revenue growth 3Y-29.19%
Revenue growth 5Y-18.69%
Sales Q2Q%141.15%

3.2 Future

The Earnings Per Share is expected to grow by 17.12% on average over the next years. This is quite good.
KDNY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 133.00% yearly.
EPS Next Y-13.68%
EPS Next 2Y-10.56%
EPS Next 3Y0.56%
EPS Next 5Y17.12%
Revenue Next Year-50.48%
Revenue Next 2Y50.65%
Revenue Next 3Y140.24%
Revenue Next 5Y133%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KDNY Yearly Revenue VS EstimatesKDNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
KDNY Yearly EPS VS EstimatesKDNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KDNY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KDNY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KDNY Price Earnings VS Forward Price EarningsKDNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KDNY Per share dataKDNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.56%
EPS Next 3Y0.56%

More info and screens

0

5. Dividend

5.1 Amount

KDNY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINOOK THERAPEUTICS INC

NASDAQ:KDNY (8/10/2023, 8:00:03 PM)

After market: 40.32 -0.07 (-0.17%)

40.39

+0.09 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2023-08-07/amc
Earnings (Next)11-08 2023-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners4.24%
Ins Owner Change0%
Market Cap2.90B
Analysts72.94
Price Target41.11 (1.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.1%
Min EPS beat(2)-13.35%
Max EPS beat(2)-4.85%
EPS beat(4)0
Avg EPS beat(4)-14.99%
Min EPS beat(4)-30.05%
Max EPS beat(4)-4.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)479.25%
Min Revenue beat(2)311.77%
Max Revenue beat(2)646.73%
Revenue beat(4)4
Avg Revenue beat(4)928.11%
Min Revenue beat(4)311.77%
Max Revenue beat(4)2351.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.54%
PT rev (3m)8.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)-0.34%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)300.54%
Revenue NY rev (3m)300.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 495.85
P/FCF N/A
P/OCF N/A
P/B 8.12
P/tB 9.77
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)-3.52
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.42
OCFYN/A
SpS0.08
BVpS4.97
TBVpS4.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.82
Quick Ratio 5.82
Altman-Z 10.57
F-Score2
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)43.03%
Cap/Depr(5y)40.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-107.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-54.1%
EPS Next Y-13.68%
EPS Next 2Y-10.56%
EPS Next 3Y0.56%
EPS Next 5Y17.12%
Revenue 1Y (TTM)-89.24%
Revenue growth 3Y-29.19%
Revenue growth 5Y-18.69%
Sales Q2Q%141.15%
Revenue Next Year-50.48%
Revenue Next 2Y50.65%
Revenue Next 3Y140.24%
Revenue Next 5Y133%
EBIT growth 1Y-192.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.95%
EBIT Next 3Y-18.27%
EBIT Next 5Y25.02%
FCF growth 1Y-110.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.88%
OCF growth 3YN/A
OCF growth 5YN/A